Comparative study on the efficacy of S-1108 and cefotiam hexetil in bacterial pneumonia

Atsushi Saito; Hiroshi Fukuhara; Jun Inadome; Hiroaki Nakamura; Akiko Miyazato; Yoshikazu Kawakami; Etsuro Yamaguchi; Akira Saito; Ichiro Nakayama; Masumi Tomizawa; Yohmei Hiraga; Mitsuhide Ohmichi; Kazuo Takebe; Toyokazu Tamura; Mitsuo Masuda; Masashi Tamura; Kazuki Konishi; Kazuo Obara; Kenichi Takeuchi; Masafumi Masuda; Haruto Hirano; Akira Watanabe; Kiyoshi Konno; Tsuneo Sayama; Satoru Shoji; Mitsunobu Honma; Kaoru Shimada; Norio Kikuchi; Atsushi Saito; Kohya Shiba; Osamu Sakai; Hiroyuki Kobayashi; Susumu Sakayori; Izumi Hayashi; Masaru Koyama; Yoshio Uzuka; Harumi Shishido; Takeshi Yamaryo; Kazuhiko Someya; Satoru Takahashi; Yoshiaki Nagayama; Shoichiro Irimajiri; Mitsuo Obana; Fumio Matsumoto; Takeo Imai; Shigeki Odagiri; Kenichi Takahashi; Takashi Ogura; Masaaki Arakawa; Kouichi Wada; Fumihide Iwata; Shigeyuki Hoshino; Hiroki Tukada; Nobuki Aoki; Osamu Sekine; Yasutoshi Suzuki; Kaoru Shimokata; Shuzo Sakai; Fumio Nomura; Hironobu Minami; Kazuyoshi Senda; Masashi Yamamoto; Toshiyuki Yamamoto; Kanzo Suzuki; Toru Matsuura; Shigeru Shirakawa; Fumio Miki; Kojiro Yasunaga; Seibun Yonezu; Yoshitaka Yamanaka; Yasuhiko Miyazaki; Nobuhiro Narita; Masayoshi Sawaki; Keiichi Mikasa; Rinzo Soejima; Toshiharu Matsushima; Makoto Kimura; Michio Yamakido; Soichiro Hozawa; Hideto Yamakido; Yoshiro Sawae; Koji Takaki; Yukio Kumagai; Satoshi Kuboi; Toshiyuki Ishimaru; Kotaro Oizumi; Yoichiro Ichikawa; Naoto Tokunaga; Kohei Hara; Shigeru Kohno; Hironobu Koga; Mitsuo Kaku; Kazunori Tomono; Naomi Ito; Osamu Sakito; Keizo Matsumoto; Tsuyoshi Nagatake; Naoto Rikitomi; Yoshiaki Utsunomiya; Masaru Nasu; Jun Goto; Kazuo Kitagawa; Mitsuyoshi Nakashima; Intetsu Kobayashi

doi:10.11250/chemotherapy1953.42.451

Comparative study on the efficacy of S-1108 and cefotiam hexetil in bacterial pneumonia

Atsushi Saito, Hiroshi Fukuhara, Jun Inadome, Hiroaki Nakamura, Akiko Miyazato, Yoshikazu Kawakami, Etsuro Yamaguchi, Akira Saito, Ichiro Nakayama, Masumi Tomizawa, Yohmei Hiraga, Mitsuhide Ohmichi, Kazuo Takebe, Toyokazu Tamura, Mitsuo Masuda, Masashi Tamura, Kazuki Konishi, Kazuo Obara, Kenichi Takeuchi, Masafumi MasudaHaruto Hirano, Akira Watanabe, Kiyoshi Konno, Tsuneo Sayama, Satoru Shoji, Mitsunobu Honma, Kaoru Shimada, Norio Kikuchi, Atsushi Saito, Kohya Shiba, Osamu Sakai, Hiroyuki Kobayashi, Susumu Sakayori, Izumi Hayashi, Masaru Koyama, Yoshio Uzuka, Harumi Shishido, Takeshi Yamaryo, Kazuhiko Someya, Satoru Takahashi, Yoshiaki Nagayama, Shoichiro Irimajiri, Mitsuo Obana, Fumio Matsumoto, Takeo Imai, Shigeki Odagiri, Kenichi Takahashi, Takashi Ogura, Masaaki Arakawa, Kouichi Wada, Fumihide Iwata, Shigeyuki Hoshino, Hiroki Tukada, Nobuki Aoki, Osamu Sekine, Yasutoshi Suzuki, Kaoru Shimokata, Shuzo Sakai, Fumio Nomura, Hironobu Minami, Kazuyoshi Senda, Masashi Yamamoto, Toshiyuki Yamamoto, Kanzo Suzuki, Toru Matsuura, Shigeru Shirakawa, Fumio Miki, Kojiro Yasunaga, Seibun Yonezu, Yoshitaka Yamanaka, Yasuhiko Miyazaki, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Rinzo Soejima, Toshiharu Matsushima, Makoto Kimura, Michio Yamakido, Soichiro Hozawa, Hideto Yamakido, Yoshiro Sawae, Koji Takaki, Yukio Kumagai, Satoshi Kuboi, Toshiyuki Ishimaru, Kotaro Oizumi, Yoichiro Ichikawa, Naoto Tokunaga, Kohei Hara, Shigeru Kohno, Hironobu Koga, Mitsuo Kaku, Kazunori Tomono, Naomi Ito, Osamu Sakito, Keizo Matsumoto, Tsuyoshi Nagatake, Naoto Rikitomi, Yoshiaki Utsunomiya, Masaru Nasu, Jun Goto, Kazuo Kitagawa, Mitsuyoshi Nakashima, Intetsu Kobayashi

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

To evaluate the efficacy, safety and usefulness of S-1108, a new ester-type oral cephem antibiotic, in bacterial pneumonia, we carried out a double-blind comparative study with cefotiam hexetil (CTM-HE) in collaborating institutions. S-1108 at a daily dose of 450 mg (divided in 3 doses) and CTM-HE at a daily dose of 600 mg (divided in 3 doses) were orally administrated for 14 days, and the following results were obtained: 1) The number of patients who were given the study drugs was 132 (S-1108 group: 64, CTM-HE group: 68). The number of evaluable patients for clinical efficacy, side effects, abnormal laboratory values and usefulness were 108 (S-1108 group: 49, CTM-HE group: 59), 126 (S-1108 group: 61, CTM-HE group: 65), 114 (S-1108 group: 61, CTM-HE group: 53) and 109 (S-1108 group: 49, CTM-HE group: 60), respectively. 2) The efficacy rates for bacterial pneumonia were 90.9% in the S-1108 group and 82.1% in the CTM-HE group, showing no significant differences between the two groups. 3) There were no significant differences between the two groups with respect to the degree of improvement in subjective and objective signs, or laboratory values except for ESR on the 7 th and 14 th day of treatment (p=0.0009 and p=0.0068, respectively), and CRP on the 3 rd day and 14th day of treatment (p=0.0160 and p=0.0440, respectively) in all of which S-1108 was superior. 4) As for the bacteriological effects, the elimination rates of causative organisms were 94.7% in the S-1108 group and 73.1% in the CTM-HE group, with no significant differences. 5) Side effects were observed in 3 patients (4.9%) in the S-1108 group and 5 patients (7.7%) in the CTM-HE group, and abnormal changes in laboratory findings in 18 patients (29.5%) in the S-1108 group and 10 patients (18.9%) in the CTM-HE group, again showing no significant differences. 6) The utility rates (satisfaction rate) for bacterial pneumonia were 90.9% in the S-1108 group and 77.2% in the CTM-HE group, with no significant differences between the two groups. The above results indicate that S-1108 in daily doses of 450 mg is as useful as CTM-HE in daily doses of 600 mg in the treatment of bacterial pneumonia.

Original language	English
Pages (from-to)	451-475
Number of pages	25
Journal	Chemotherapy
Volume	42
Issue number	4
DOIs	https://doi.org/10.11250/chemotherapy1953.42.451
Publication status	Published - 1994
Externally published	Yes

Keywords

Bacterial penumoniae
Double blind study
S-1108
cefotiam hexetil

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.42.451

Cite this

Saito, A., Fukuhara, H., Inadome, J., Nakamura, H., Miyazato, A., Kawakami, Y., Yamaguchi, E., Saito, A., Nakayama, I., Tomizawa, M., Hiraga, Y., Ohmichi, M., Takebe, K., Tamura, T., Masuda, M., Tamura, M., Konishi, K., Obara, K., Takeuchi, K., ... Kobayashi, I. (1994). Comparative study on the efficacy of S-1108 and cefotiam hexetil in bacterial pneumonia. Chemotherapy, 42(4), 451-475. https://doi.org/10.11250/chemotherapy1953.42.451

Saito, A, Fukuhara, H, Inadome, J, Nakamura, H, Miyazato, A, Kawakami, Y, Yamaguchi, E, Saito, A, Nakayama, I, Tomizawa, M, Hiraga, Y, Ohmichi, M, Takebe, K, Tamura, T, Masuda, M, Tamura, M, Konishi, K, Obara, K, Takeuchi, K, Masuda, M, Hirano, H, Watanabe, A, Konno, K, Sayama, T, Shoji, S, Honma, M, Shimada, K, Kikuchi, N, Saito, A, Shiba, K, Sakai, O, Kobayashi, H, Sakayori, S, Hayashi, I, Koyama, M, Uzuka, Y, Shishido, H, Yamaryo, T, Someya, K, Takahashi, S, Nagayama, Y, Irimajiri, S, Obana, M, Matsumoto, F, Imai, T, Odagiri, S, Takahashi, K, Ogura, T, Arakawa, M, Wada, K, Iwata, F, Hoshino, S, Tukada, H, Aoki, N, Sekine, O, Suzuki, Y, Shimokata, K, Sakai, S, Nomura, F, Minami, H, Senda, K, Yamamoto, M, Yamamoto, T, Suzuki, K, Matsuura, T, Shirakawa, S, Miki, F, Yasunaga, K, Yonezu, S, Yamanaka, Y, Miyazaki, Y, Narita, N, Sawaki, M, Mikasa, K, Soejima, R, Matsushima, T, Kimura, M, Yamakido, M, Hozawa, S, Yamakido, H, Sawae, Y, Takaki, K, Kumagai, Y, Kuboi, S, Ishimaru, T, Oizumi, K, Ichikawa, Y, Tokunaga, N, Hara, K, Kohno, S, Koga, H, Kaku, M, Tomono, K, Ito, N, Sakito, O, Matsumoto, K, Nagatake, T, Rikitomi, N, Utsunomiya, Y, Nasu, M, Goto, J, Kitagawa, K, Nakashima, M & Kobayashi, I 1994, 'Comparative study on the efficacy of S-1108 and cefotiam hexetil in bacterial pneumonia', Chemotherapy, vol. 42, no. 4, pp. 451-475. https://doi.org/10.11250/chemotherapy1953.42.451

@article{b80b5695264b4098af7dd724b7f1eb15,

title = "Comparative study on the efficacy of S-1108 and cefotiam hexetil in bacterial pneumonia",

abstract = "To evaluate the efficacy, safety and usefulness of S-1108, a new ester-type oral cephem antibiotic, in bacterial pneumonia, we carried out a double-blind comparative study with cefotiam hexetil (CTM-HE) in collaborating institutions. S-1108 at a daily dose of 450 mg (divided in 3 doses) and CTM-HE at a daily dose of 600 mg (divided in 3 doses) were orally administrated for 14 days, and the following results were obtained: 1) The number of patients who were given the study drugs was 132 (S-1108 group: 64, CTM-HE group: 68). The number of evaluable patients for clinical efficacy, side effects, abnormal laboratory values and usefulness were 108 (S-1108 group: 49, CTM-HE group: 59), 126 (S-1108 group: 61, CTM-HE group: 65), 114 (S-1108 group: 61, CTM-HE group: 53) and 109 (S-1108 group: 49, CTM-HE group: 60), respectively. 2) The efficacy rates for bacterial pneumonia were 90.9% in the S-1108 group and 82.1% in the CTM-HE group, showing no significant differences between the two groups. 3) There were no significant differences between the two groups with respect to the degree of improvement in subjective and objective signs, or laboratory values except for ESR on the 7 th and 14 th day of treatment (p=0.0009 and p=0.0068, respectively), and CRP on the 3 rd day and 14th day of treatment (p=0.0160 and p=0.0440, respectively) in all of which S-1108 was superior. 4) As for the bacteriological effects, the elimination rates of causative organisms were 94.7% in the S-1108 group and 73.1% in the CTM-HE group, with no significant differences. 5) Side effects were observed in 3 patients (4.9%) in the S-1108 group and 5 patients (7.7%) in the CTM-HE group, and abnormal changes in laboratory findings in 18 patients (29.5%) in the S-1108 group and 10 patients (18.9%) in the CTM-HE group, again showing no significant differences. 6) The utility rates (satisfaction rate) for bacterial pneumonia were 90.9% in the S-1108 group and 77.2% in the CTM-HE group, with no significant differences between the two groups. The above results indicate that S-1108 in daily doses of 450 mg is as useful as CTM-HE in daily doses of 600 mg in the treatment of bacterial pneumonia.",

keywords = "Bacterial penumoniae, Double blind study, S-1108, cefotiam hexetil",

author = "Atsushi Saito and Hiroshi Fukuhara and Jun Inadome and Hiroaki Nakamura and Akiko Miyazato and Yoshikazu Kawakami and Etsuro Yamaguchi and Akira Saito and Ichiro Nakayama and Masumi Tomizawa and Yohmei Hiraga and Mitsuhide Ohmichi and Kazuo Takebe and Toyokazu Tamura and Mitsuo Masuda and Masashi Tamura and Kazuki Konishi and Kazuo Obara and Kenichi Takeuchi and Masafumi Masuda and Haruto Hirano and Akira Watanabe and Kiyoshi Konno and Tsuneo Sayama and Satoru Shoji and Mitsunobu Honma and Kaoru Shimada and Norio Kikuchi and Atsushi Saito and Kohya Shiba and Osamu Sakai and Hiroyuki Kobayashi and Susumu Sakayori and Izumi Hayashi and Masaru Koyama and Yoshio Uzuka and Harumi Shishido and Takeshi Yamaryo and Kazuhiko Someya and Satoru Takahashi and Yoshiaki Nagayama and Shoichiro Irimajiri and Mitsuo Obana and Fumio Matsumoto and Takeo Imai and Shigeki Odagiri and Kenichi Takahashi and Takashi Ogura and Masaaki Arakawa and Kouichi Wada and Fumihide Iwata and Shigeyuki Hoshino and Hiroki Tukada and Nobuki Aoki and Osamu Sekine and Yasutoshi Suzuki and Kaoru Shimokata and Shuzo Sakai and Fumio Nomura and Hironobu Minami and Kazuyoshi Senda and Masashi Yamamoto and Toshiyuki Yamamoto and Kanzo Suzuki and Toru Matsuura and Shigeru Shirakawa and Fumio Miki and Kojiro Yasunaga and Seibun Yonezu and Yoshitaka Yamanaka and Yasuhiko Miyazaki and Nobuhiro Narita and Masayoshi Sawaki and Keiichi Mikasa and Rinzo Soejima and Toshiharu Matsushima and Makoto Kimura and Michio Yamakido and Soichiro Hozawa and Hideto Yamakido and Yoshiro Sawae and Koji Takaki and Yukio Kumagai and Satoshi Kuboi and Toshiyuki Ishimaru and Kotaro Oizumi and Yoichiro Ichikawa and Naoto Tokunaga and Kohei Hara and Shigeru Kohno and Hironobu Koga and Mitsuo Kaku and Kazunori Tomono and Naomi Ito and Osamu Sakito and Keizo Matsumoto and Tsuyoshi Nagatake and Naoto Rikitomi and Yoshiaki Utsunomiya and Masaru Nasu and Jun Goto and Kazuo Kitagawa and Mitsuyoshi Nakashima and Intetsu Kobayashi",

year = "1994",

doi = "10.11250/chemotherapy1953.42.451",

language = "English",

volume = "42",

pages = "451--475",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "4",

}

TY - JOUR

T1 - Comparative study on the efficacy of S-1108 and cefotiam hexetil in bacterial pneumonia

AU - Saito, Atsushi

AU - Fukuhara, Hiroshi

AU - Inadome, Jun

AU - Nakamura, Hiroaki

AU - Miyazato, Akiko

AU - Kawakami, Yoshikazu

AU - Yamaguchi, Etsuro

AU - Saito, Akira

AU - Nakayama, Ichiro

AU - Tomizawa, Masumi

AU - Hiraga, Yohmei

AU - Ohmichi, Mitsuhide

AU - Takebe, Kazuo

AU - Tamura, Toyokazu

AU - Masuda, Mitsuo

AU - Tamura, Masashi

AU - Konishi, Kazuki

AU - Obara, Kazuo

AU - Takeuchi, Kenichi

AU - Masuda, Masafumi

AU - Hirano, Haruto

AU - Watanabe, Akira

AU - Konno, Kiyoshi

AU - Sayama, Tsuneo

AU - Shoji, Satoru

AU - Honma, Mitsunobu

AU - Shimada, Kaoru

AU - Kikuchi, Norio

AU - Saito, Atsushi

AU - Shiba, Kohya

AU - Sakai, Osamu

AU - Kobayashi, Hiroyuki

AU - Sakayori, Susumu

AU - Hayashi, Izumi

AU - Koyama, Masaru

AU - Uzuka, Yoshio

AU - Shishido, Harumi

AU - Yamaryo, Takeshi

AU - Someya, Kazuhiko

AU - Takahashi, Satoru

AU - Nagayama, Yoshiaki

AU - Irimajiri, Shoichiro

AU - Obana, Mitsuo

AU - Matsumoto, Fumio

AU - Imai, Takeo

AU - Odagiri, Shigeki

AU - Takahashi, Kenichi

AU - Ogura, Takashi

AU - Arakawa, Masaaki

AU - Wada, Kouichi

AU - Iwata, Fumihide

AU - Hoshino, Shigeyuki

AU - Tukada, Hiroki

AU - Aoki, Nobuki

AU - Sekine, Osamu

AU - Suzuki, Yasutoshi

AU - Shimokata, Kaoru

AU - Sakai, Shuzo

AU - Nomura, Fumio

AU - Minami, Hironobu

AU - Senda, Kazuyoshi

AU - Yamamoto, Masashi

AU - Yamamoto, Toshiyuki

AU - Suzuki, Kanzo

AU - Matsuura, Toru

AU - Shirakawa, Shigeru

AU - Miki, Fumio

AU - Yasunaga, Kojiro

AU - Yonezu, Seibun

AU - Yamanaka, Yoshitaka

AU - Miyazaki, Yasuhiko

AU - Narita, Nobuhiro

AU - Sawaki, Masayoshi

AU - Mikasa, Keiichi

AU - Soejima, Rinzo

AU - Matsushima, Toshiharu

AU - Kimura, Makoto

AU - Yamakido, Michio

AU - Hozawa, Soichiro

AU - Yamakido, Hideto

AU - Sawae, Yoshiro

AU - Takaki, Koji

AU - Kumagai, Yukio

AU - Kuboi, Satoshi

AU - Ishimaru, Toshiyuki

AU - Oizumi, Kotaro

AU - Ichikawa, Yoichiro

AU - Tokunaga, Naoto

AU - Hara, Kohei

AU - Kohno, Shigeru

AU - Koga, Hironobu

AU - Kaku, Mitsuo

AU - Tomono, Kazunori

AU - Ito, Naomi

AU - Sakito, Osamu

AU - Matsumoto, Keizo

AU - Nagatake, Tsuyoshi

AU - Rikitomi, Naoto

AU - Utsunomiya, Yoshiaki

AU - Nasu, Masaru

AU - Goto, Jun

AU - Kitagawa, Kazuo

AU - Nakashima, Mitsuyoshi

AU - Kobayashi, Intetsu

PY - 1994

Y1 - 1994

N2 - To evaluate the efficacy, safety and usefulness of S-1108, a new ester-type oral cephem antibiotic, in bacterial pneumonia, we carried out a double-blind comparative study with cefotiam hexetil (CTM-HE) in collaborating institutions. S-1108 at a daily dose of 450 mg (divided in 3 doses) and CTM-HE at a daily dose of 600 mg (divided in 3 doses) were orally administrated for 14 days, and the following results were obtained: 1) The number of patients who were given the study drugs was 132 (S-1108 group: 64, CTM-HE group: 68). The number of evaluable patients for clinical efficacy, side effects, abnormal laboratory values and usefulness were 108 (S-1108 group: 49, CTM-HE group: 59), 126 (S-1108 group: 61, CTM-HE group: 65), 114 (S-1108 group: 61, CTM-HE group: 53) and 109 (S-1108 group: 49, CTM-HE group: 60), respectively. 2) The efficacy rates for bacterial pneumonia were 90.9% in the S-1108 group and 82.1% in the CTM-HE group, showing no significant differences between the two groups. 3) There were no significant differences between the two groups with respect to the degree of improvement in subjective and objective signs, or laboratory values except for ESR on the 7 th and 14 th day of treatment (p=0.0009 and p=0.0068, respectively), and CRP on the 3 rd day and 14th day of treatment (p=0.0160 and p=0.0440, respectively) in all of which S-1108 was superior. 4) As for the bacteriological effects, the elimination rates of causative organisms were 94.7% in the S-1108 group and 73.1% in the CTM-HE group, with no significant differences. 5) Side effects were observed in 3 patients (4.9%) in the S-1108 group and 5 patients (7.7%) in the CTM-HE group, and abnormal changes in laboratory findings in 18 patients (29.5%) in the S-1108 group and 10 patients (18.9%) in the CTM-HE group, again showing no significant differences. 6) The utility rates (satisfaction rate) for bacterial pneumonia were 90.9% in the S-1108 group and 77.2% in the CTM-HE group, with no significant differences between the two groups. The above results indicate that S-1108 in daily doses of 450 mg is as useful as CTM-HE in daily doses of 600 mg in the treatment of bacterial pneumonia.

AB - To evaluate the efficacy, safety and usefulness of S-1108, a new ester-type oral cephem antibiotic, in bacterial pneumonia, we carried out a double-blind comparative study with cefotiam hexetil (CTM-HE) in collaborating institutions. S-1108 at a daily dose of 450 mg (divided in 3 doses) and CTM-HE at a daily dose of 600 mg (divided in 3 doses) were orally administrated for 14 days, and the following results were obtained: 1) The number of patients who were given the study drugs was 132 (S-1108 group: 64, CTM-HE group: 68). The number of evaluable patients for clinical efficacy, side effects, abnormal laboratory values and usefulness were 108 (S-1108 group: 49, CTM-HE group: 59), 126 (S-1108 group: 61, CTM-HE group: 65), 114 (S-1108 group: 61, CTM-HE group: 53) and 109 (S-1108 group: 49, CTM-HE group: 60), respectively. 2) The efficacy rates for bacterial pneumonia were 90.9% in the S-1108 group and 82.1% in the CTM-HE group, showing no significant differences between the two groups. 3) There were no significant differences between the two groups with respect to the degree of improvement in subjective and objective signs, or laboratory values except for ESR on the 7 th and 14 th day of treatment (p=0.0009 and p=0.0068, respectively), and CRP on the 3 rd day and 14th day of treatment (p=0.0160 and p=0.0440, respectively) in all of which S-1108 was superior. 4) As for the bacteriological effects, the elimination rates of causative organisms were 94.7% in the S-1108 group and 73.1% in the CTM-HE group, with no significant differences. 5) Side effects were observed in 3 patients (4.9%) in the S-1108 group and 5 patients (7.7%) in the CTM-HE group, and abnormal changes in laboratory findings in 18 patients (29.5%) in the S-1108 group and 10 patients (18.9%) in the CTM-HE group, again showing no significant differences. 6) The utility rates (satisfaction rate) for bacterial pneumonia were 90.9% in the S-1108 group and 77.2% in the CTM-HE group, with no significant differences between the two groups. The above results indicate that S-1108 in daily doses of 450 mg is as useful as CTM-HE in daily doses of 600 mg in the treatment of bacterial pneumonia.

KW - Bacterial penumoniae

KW - Double blind study

KW - S-1108

KW - cefotiam hexetil

UR - http://www.scopus.com/inward/record.url?scp=0028246976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028246976&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.42.451

DO - 10.11250/chemotherapy1953.42.451

M3 - Article

AN - SCOPUS:0028246976

SN - 0009-3165

VL - 42

SP - 451

EP - 475

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

IS - 4

ER -

Comparative study on the efficacy of S-1108 and cefotiam hexetil in bacterial pneumonia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this